New drugs for exacerbations of chronic obstructive pulmonary disease

The Lancet ◽  
2009 ◽  
Vol 374 (9691) ◽  
pp. 744-755 ◽  
Author(s):  
Trevor T Hansel ◽  
Peter J Barnes
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
New Drugs ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

scholarly journals Pharmacological treatment and current controversies in COPD

F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 1533 ◽  
Author(s):  
Mario Cazzola ◽  
Paola Rogliani ◽  
Daiana Stolz ◽  
Maria Gabriella Matera
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lung Disease ◽  
Pulmonary Disease ◽  
Pharmacological Treatment ◽  
Obstructive Lung Disease ◽  
Chronic Obstructive Lung Disease ◽  
New Drugs ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Global Initiative

Bronchodilators, corticosteroids, and antibiotics are still key elements for treating chronic obstructive pulmonary disease in the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations and this is due in part to our current inability to discover new drugs capable of decisively influencing the course of the disease. However, in recent years, information has been produced that, if used correctly, can allow us to improve the use of the available therapies.

scholarly journals New possibilities of pharmacotherapy for chronic obstructive pulmonary disease

2018 ◽  
pp. 28-37
Author(s):  
A. I. Sinopalnikov ◽  
A. G. Romanovskikh ◽  
Yu. G. Belotserkovskaya
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Therapeutic Strategy ◽  
New Drugs ◽  
Fixed Dose ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Long Acting

The use of bronchodilators (DB) remains up to the present day the leading therapeutic strategy for the treatment of chronic obstructive pulmonary disease (COPD), in which case administration of fixed-dose combinations of long-acting bronchodilators seem the most promising. At the same time, the issues of anti-inflammatory therapy of COPD are also actively discussed, first of which is feasibility for the wide use of fixed-dose combinations of inhaled glucocorticosteroids (IHGC) with long-acting β2-agonists (LABA). Recent years are characterized by the launch of a significant number of new BDs, anti-inflammatory drugs and their combinations to the pharmaceutical market. The article considers the role and place of new drugs in the treatment of COPD having a stable course.

scholarly journals Anti-Inflammatory Function of Fatty Acids and Involvement of Their Metabolites in the Resolution of Inflammation in Chronic Obstructive Pulmonary Disease

2021 ◽  
Vol 22 (23) ◽  
pp. 12803
Author(s):  
Stanislav Kotlyarov ◽  
Anna Kotlyarova
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Fatty Acids ◽  
Lipid Metabolism ◽  
Pulmonary Disease ◽  
Unsaturated Fatty Acids ◽  
New Drugs ◽  
Chronic Obstructive ◽  
Resolution Of Inflammation ◽  
Obstructive Pulmonary Disease ◽  
Mediators Of Inflammation

Lipid metabolism plays an important role in many lung functions. Disorders of lipid metabolism are part of the pathogenesis of chronic obstructive pulmonary disease (COPD). Lipids are involved in numerous cross-linkages with inflammation. Recent studies strongly support the involvement of fatty acids as participants in inflammation. They are involved in the initiation and resolution of inflammation, including acting as a substrate for the formation of lipid mediators of inflammation resolution. Specialized pro-inflammatory mediators (SPMs) belonging to the classes of lipoxins, resolvins, maresins, and protectins, which are formed enzymatically from unsaturated fatty acids, are now described. Disorders of their production and function are part of the pathogenesis of COPD. SPMs are currently the subject of active research in order to find new drugs. Short-chain fatty acids are another important participant in metabolic and immune processes, and their role in the pathogenesis of COPD is of great clinical interest.

scholarly journals Management Options in Chronic Obstructive Pulmonary Disease

2012 ◽  
Vol 4 ◽  
pp. CMT.S6563
Author(s):  
Himanshu Desai ◽  
Bhavin Dalal
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Smoking Cessation ◽  
Pulmonary Disease ◽  
Respiratory Disease ◽  
Team Work ◽  
New Drugs ◽  
Chronic Obstructive ◽  
Management Options ◽  
Obstructive Pulmonary Disease ◽  
Systemic Involvement

Chronic obstructive pulmonary disease (COPD) is a leading respiratory disease in the world and third leading cause of death in United States. COPD is not recognized as an isolated respiratory disease anymore; in fact it is one of the dreaded diseases with significant systemic involvement and complications. Treatment of COPD requires team work and efforts among physicians, nurses, respiratory therapists and physical therapists. Treatment of patients with frequent exacerbations is a heavy burden on healthcare network. In the last few years, some improvements in the management of COPD have been made, owing to new drugs and management strategies, along with non-pharmacologic treatment of COPD with pulmonary rehabilitation and surgical interventions. Smoking cessation is still the best strategy to prevent COPD and prevent further progression of disease. In this review, we discuss pharmacotherapy of COPD including management of acute exacerbations, pharmacotherapy for smoking cessation and role of vaccination in COPD patients.

Oral and Oropharyngeal Sensory Function in Adults With Chronic Obstructive Pulmonary Disease

2020 ◽  
Vol 29 (2) ◽  
pp. 864-872
Author(s):  
Fernanda Borowsky da Rosa ◽  
Adriane Schmidt Pasqualoto ◽  
Catriona M. Steele ◽  
Renata Mancopes
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Oral Cavity ◽  
Pulmonary Disease ◽  
Thermal Sensation ◽  
Sensory Function ◽  
Control Group ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Age Related ◽  
Copd Patients

Introduction The oral cavity and pharynx have a rich sensory system composed of specialized receptors. The integrity of oropharyngeal sensation is thought to be fundamental for safe and efficient swallowing. Chronic obstructive pulmonary disease (COPD) patients are at risk for oropharyngeal sensory impairment due to frequent use of inhaled medications and comorbidities including gastroesophageal reflux disease. Objective This study aimed to describe and compare oral and oropharyngeal sensory function measured using noninstrumental clinical methods in adults with COPD and healthy controls. Method Participants included 27 adults (18 men, nine women) with a diagnosis of COPD and a mean age of 66.56 years ( SD = 8.68). The control group comprised 11 healthy adults (five men, six women) with a mean age of 60.09 years ( SD = 11.57). Spirometry measures confirmed reduced functional expiratory volumes (% predicted) in the COPD patients compared to the control participants. All participants completed a case history interview and underwent clinical evaluation of oral and oropharyngeal sensation by a speech-language pathologist. The sensory evaluation explored the detection of tactile and temperature stimuli delivered by cotton swab to six locations in the oral cavity and two in the oropharynx as well as identification of the taste of stimuli administered in 5-ml boluses to the mouth. Analyses explored the frequencies of accurate responses regarding stimulus location, temperature and taste between groups, and between age groups (“≤ 65 years” and “> 65 years”) within the COPD cohort. Results We found significantly higher frequencies of reported use of inhaled medications ( p < .001) and xerostomia ( p = .003) in the COPD cohort. Oral cavity thermal sensation ( p = .009) was reduced in the COPD participants, and a significant age-related decline in gustatory sensation was found in the COPD group ( p = .018). Conclusion This study found that most of the measures of oral and oropharyngeal sensation remained intact in the COPD group. Oral thermal sensation was impaired in individuals with COPD, and reduced gustatory sensation was observed in the older COPD participants. Possible links between these results and the use of inhaled medication by individuals with COPD are discussed.

Sign in / Sign up

Export Citation Format

Share Document